论文部分内容阅读
自2000年美国MayoClinic的Malinchoc等[1]最初创立终末期肝病模型(MELD)评分以来,随后的研究证实其为不同的终末期肝病生存率的预测指标[2],2002年美国器官分配网络(UNOS)正式将MELD评分作为确定肝移植器官分配优先权的标准[3],近年来随附加血清钠的MELD评分系统的提出[4-7],除肝移植器官分配之外,亦被广泛应用于有肝硬化并发症,肝炎以及暴发性肝功能衰竭等疾病生存率预测,本文仅就该领域国外研究进展加以综述如下。
Since 2000, the MayoClinic of the United States, Malinchoc et al [1] initially created the end-stage liver disease model (MELD) score, subsequent studies confirmed that it is a different predictor of end-stage liver disease survival [2], 2002 American Organ Distribution Network UNOS formally use MELD score as the standard to determine the priority of organ allocation in liver transplantation [3]. In recent years, MELD scoring system with added serum sodium [4-7] has been widely used in addition to liver transplantation organ distribution In cirrhotic complications, hepatitis and fulminant hepatic failure disease survival prediction, this article only on the field of foreign research progress to be summarized as follows.